Kirby Patrick Gardner

Mr. Kirby Patrick Gardner

Rutgers, The State University of New Jersey, New Brunswick, New Jersey, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in JCO Precision Oncology
Verified
Journal Article
Open access
JMJillian A. Moran
Jillian A. Moran
DADaniel L Adams
Daniel L Adams
MEMartin J. Edelman
Martin J. Edelman
PLPablo Lopez
Pablo Lopez
JHJianzhong He
Jianzhong He
SLSteven Lin
Steven Lin
PURPOSE: Current diagnostic methods to determine programmed death 1 (PD-1) receptor and its ligand (PD-L1)/PD-1 immunotherapy (immune checkpoint inhibitor [ICI]) efficacy in recurrent or metastatic non–small-cell lung carcinoma (rmNSCLC) are imprecise. Although previously shown that patients with high tumor PD-L1 (≥ 50%) demonstrate clinical benefit in the form of disease reduction and improved survival, patients with low PD-L1 (< 50%) sometimes benefit from treatment. Since the PD-L1/PD-1 pathway is dynamic, monitoring PD-L1 levels during treatment may be more accurate than a static baseline tumor biopsy; however, rebiopsying the primary or metastatic disease is rarely feasible. Liquid biopsies that measure the upregulation of PD-L1 on tumor-associated cells (TACs), ie, cancer-associated macrophage-like cells and circulating tumor cells, have been performed, but their predictive value for ICI therapy efficacy is unknown. MATERIALS AND METHODS: We initiated a single-blind prospective study to evaluate TAC PD-L1 expression changes in rmNSCLC from blood samples before (T0) and after (T1) treatment with ICI (ICI, n = 41) or without ICI (no ICI, n = 41). Anonymized blood was filtered to isolate TACs, which were then quantified for high/low PD-L1 expression. Progression-free survival (PFS) or overall survival (OS) hazard ratios (HRs) were evaluated at 18 and 24 months by censored univariate analysis. RESULTS: Increased TAC PD-L1 expression between T0 and T1 in patients who were not treated with ICI had no relationship with PFS or OS. However, increased TAC PD-L1 expression between T0 and T1 in patients treated with ICI had significantly better PFS (HR, 3.49; 95% CI, 1.5 to 8.3; P = .0091) and OS (HR, 3.058; 95% CI, 1.2 to 7.9; P = .0410). CONCLUSION: Blood-based monitoring of dynamic changes in PD-L1 in TACs appears to identify patients with rmNSCLC who may benefit from ICI.

19 March 2021 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
KGKirby Patrick Gardner
Kirby Patrick Gardner
MAMohammed Aldakkak
Mohammed Aldakkak
CTCha-Mei Tang
Cha-Mei Tang
STSusan Tsai
Susan Tsai
DADaniel L Adams
Daniel L Adams
Pancreatic cancer (PC) is notoriously difficult to diagnosis and properly stage resulting in incorrect primary treatment. Diagnostic and prognostic biomarkers are desperately needed to more accurately stage patients and select proper treatments. Recently, a newly discovered circulating stromal cell, i.e. cancer associated macrophage-like cell (CAML), was found to accurately identify solid cancers and predict for worse prognosis. In this pilot study, blood samples were procured from 63 PC patients prior to start of therapeutic intent. CAMLs were found in 95% of samples tested, with ≥12 CAMLs/7.5 mL and ≥50 µm CAMLs both predicting for advanced pathological stage and progression free survival. These data suggest that CAML assessment prior to treatment of PC predicts patients with under-staged disease and with more aggressive PC less likely to respond to standard of care treatment.

8 March 2022 in PLOS ONE
Verified
Journal Article
Open access
PDF file
KGKirby Patrick Gardner
Kirby Patrick Gardner
STSusan Tsai
Susan Tsai
MAMohammed Aldakkak
Mohammed Aldakkak
SGStephen Gironda
Stephen Gironda
DADaniel L Adams
Daniel L Adams
The aggressive nature and metastatic potential of pancreatic cancer (PC) results in poor prognosis and high mortality. A better understanding of the underlying biology of PC and the ability of tumor cells to spread to distant sites is needed to advance the treatment of PC. The chemokine receptor CXCR4 has been heavily implicated in the spread and mobility of many solid cancers based on its role in cancer cell chemotaxis as well as increased metastatic potential. To better elucidate CXCR4’s role in the metastatic spread of PC, we examined its expression on various tumor associated cells (TACs) in the peripheral blood of PC patients, including circulating tumor cells (CTCs), epithelial to mesenchymal transition cells (EMTs), and cancer associated macrophage-like cells (CAMLs). In this pilot study, blood samples were procured from 30 PC patients prior to the start of therapeutic intent. CXCR4 expression was analyzed on TACs captured from the blood samples and evaluated in relation to cell migration as well as patient clinical outcomes. In total, CTCs, EMTs, and CAMLs were found in 27%, 60%, and 97% of PC patients, respectively. High CXCR4 expression in CTCs, CAMLs, and EMTs was found to significantly relate to their increased numbers in circulation. Further, higher expression of CXCR4 in CAMLs and EMTs was significantly related to faster progression and worse survival. These data suggest that CXCR4 expression in PC is strongly related to the intravasation and presence of TACs into circulation, as well as being a possible biomarker for aggressive metastatic disease.

Verified
Journal Article
Open access
PDF file
KGKirby Patrick Gardner
Kirby Patrick Gardner
MCMassimo Cristofanilli
Massimo Cristofanilli
SCSaranya Chumsri
Saranya Chumsri
RLRena Lapidus
Rena Lapidus
CTCha-Mei Tang
Cha-Mei Tang
DADaniel L Adams
Daniel L Adams
The usage of beta blockers in breast cancer (BC) patients is implicated in the reduction in distant metastases, cancer recurrence, and cancer mortality. Studies suggest that the adrenergic pathway is directly involved in sympathetic-driven hematopoietic activation of pro-tumor microenvironmental proliferation and tumor cell trafficking into the circulation. Cancer-associated macrophage-like cells (CAMLs) are pro-tumor polynucleated monocytic cells of hematopoietic origin emanating from tumors which may aid in circulating tumor cell (CTC) dissemination into the circulation. We examined the linkage between Beta-2 adrenergic receptor (B2AR) signaling in CAMLs and CTCs by establishing expression profiles in a model BC cell line (MDA-MB-231). We compared the model to CAMLs and CTCs found in patents. Although internalization events were observed in patients, differences were found in the expression of B2AR between the tumor cell lines and the CAMLs found in patients. High B2AR expression on patients’ CAMLs was correlated with significantly more CAMLs in the circulation (p = 0.0093), but CTCs had no numerical relationship (p = 0.1565). High B2AR CAML expression was also significantly associated with a larger size of CAMLs (p = 0.0073), as well as being significantly associated with shorter progression-free survival (p = 0.0097) and overall survival (p = 0.0265). These data suggest that B2AR expression on CAMLs is closely related to the activation, intravasation, and growth of CAMLs in the circulation.

11 November 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
DKDimpal M. Kasabwala
Dimpal M. Kasabwala
RBRaymond Bergan
Raymond Bergan
KGKirby Patrick Gardner
Kirby Patrick Gardner
RLRena Lapidus
Rena Lapidus
STSusan Tsai
Susan Tsai
DADaniel L Adams
Daniel L Adams
Micronuclei (MN) are fragments of damaged nucleic acids which budded from a cell’s nuclei as a repair mechanism for chromosomal instabilities, which within circulating white blood cells (cWBCs) signifies increased cancer risk, and in tumor cells indicates aggressive subtypes. MN form overtime and with therapy induction, which requires sequential monitoring of rarer cell subpopulations. We evaluated the peripheral blood (7.5 mL) for MN in Circulating Stromal Cells (CStCs) in a prospective pilot study of advanced colorectal cancer patients (n = 25), identifying MN by DAPI+ structures (<3 µm) within the cellular cytoplasm. MN+ was compared to genotoxic induction, progression free survival (PFS) or overall survival (OS) hazard ratios (HR) over three years. MN were identified in 44% (n = 11/25) of CStCs, but were not associated with genotoxic therapies (p = 0.110) nor stage (p = 0.137). However, presence of MN in CStCs was independently prognostic for PFS (HR = 17.2, 95% CI 3.6–80.9, p = 0.001) and OS (HR = 70.3, 95% CI 6.6–752.8, p = 0.002), indicating a non-interventional mechanism in their formation. Additionally, MN formation did not appear associated with chemotherapy induction, but was correlated with tumor response. MN formation in colorectal cancer is an underlying biological mechanism that appears independent of chemotherapeutic genotoxins, changes during treatment, and predicts for poor clinical outcomes.

1 July 2026 in JCO Precision Oncology
Verified
Journal Article
Closed access
MEMartin J. Edelman
Martin J. Edelman
AVAnil Vachani
Anil Vachani
DZDana Marie Haagen Zambino
Dana Marie Haagen Zambino
EREric Ross
Eric Ross
RKRohit Kumar
Rohit Kumar
DADaniel L Adams
Daniel L Adams
PURPOSE: Cancer-associated macrophage-like cells (CAMLs) are specialized myeloid polyploid cells that emanate from primary tumor masses and transit circulation in a variety of malignancies, which have the potential to track cancer progression and therapy response. Previous studies have demonstrated that larger CAMLs (≥30 μM and ≥50 μM) are particularly associated with disease progression. We hypothesized that CAMLs could provide additional cancer risk information for patients with indeterminate lung nodules. MATERIALS AND METHODS: This was a double-blind, multicenter study to evaluate CAMLs in the blood as diagnostic biomarkers for malignancy. We enrolled 203 patients with indeterminate nodules (0.8-3 cm) and no diagnosis of cancer. Blood samples were obtained at the time of the initial evaluation and before diagnostic procedures; physicians were blinded to the CAML results. We determined the prevalence of CAMLs ≥30 μM (CAML+) at the initial screening and calculated screening statistics including positive predictive value (PPV), negative predictive value (NPV), sensitivity, and specificity of CAML+ for any malignancy detected during follow-up. RESULTS: Of the 203 enrolled patients, 200 had their samples sent for CAML analysis. For evaluable patients (n = 191), there were 41 with non–small cell lung cancer, four with small cell lung cancer, six with carcinoid, and five with other malignancies. For eight patients, a biopsy was either nondiagnostic or not feasible; they were treated for lung cancer with radiotherapy (and counted as cancer). CAMLs were detected in 45.0% of all patient samples (95% CI, 37.8% to 52.4%). For the detection of any malignancy, CAML PPV and NPV were 27.9% and 61.9%, respectively, and sensitivity and specificity were 37.5% and 51.2%, respectively. Defining CAML+ as larger CAML size (≥50 μM) did not significantly alter the results. CONCLUSION: CAMLs are neither sensitive nor specific to the presence of malignancy in indeterminate pulmonary nodules.